MediRox APTT liquid reagent is used for in vitro determination of the Activated Partial Thromboplastin Time (APTT). APTT is measured to obtain a global evaluation of the intrinsic pathway and for monitoring heparin anticoagulant therapy. The MediRox APTT reagent has been designed to provide an extra long reaction time in order to obtain a high resolution for clearest interpretation of results.
Liquid components, ready to use
Colloidal silicate contact activator
Insensitive to Lupus Anticoagulant
Highly sensitive to Heparin
Excellent factor sensitivity
Activated partial thromboplastin time (APTT) is a commonly used screening test for haemostatic defects in the intrinsic and common pathway of the coagulation cascade, as well as the contact activation system. Thus, FV, FVIII, FIX, FX, FXI, FXII, prekallikrein and high‐molecular weight kininogen deficiencies can result in a prolonged APTT. Moreover, APTT is also suitable to monitor heparin treatment and, depending on the design of the reagent, for detection of lupus anticoagulant (LA). Since there is no international standard for APTT to correlate against, each APTT on the market has its own composition of phospholipids and activator, giving reagents different characteristics.
MRX APTT can be characterised as heparin, FVIII, FIX, FXI sensitive, while still being insensitive to presence of LA, since LA can cause a falsely pro-longed APTT. Thus it is suitable to monitor heparin treatment and for haemophilia screening, while less suitable to detect LA.
MRX APTT reagent utilises a near colloidal contact activator to stimulate generation of FXIa by providing a surface for the interaction of high molecular weight kininogen, kallikrein and FXIIa. The contact activation is allowed to proceed at 37 °C for a period of time before calcium chloride is added to trigger further reactions and finally a formation of fibrin clot.
MRX APTT reagent contains phospholipids and silicate to ensure a highly consistent and stable product. The product is designed to be insensitive to LA and to have high sensitivity to heparin.
Sensitivity & Specificity
Details & Typical Data
|Product form:||Liquid components|
|Normal Range:||<35 sec|
|Abnormal Range:||>35 sec|
|Heparin||APTT clotting time|
|0 IU/mL||30 sec|
|0,2 IU/mL||70 sec|
|0,4 IU/mL||174 sec|
|<1%||86 sec||71 sec||92 sec|
|10%||46 sec||44 sec||51 sec|
|40%||34 sec||34 sec||34 sec|
|100%||29 sec||29 sec||29 sec|
Stability & Storage
|Shelf life:||24 months at 2-8 °C|
|Open vial stability:||30 days at 2-8 °C|
|Reference Number||Product Description||Pack Size|
|MRX930||Small APTT Kit||5x5 mL APTT + 5x5 mL CaCl₂|
|MRX931||Large APTT Kit||5x10 mL APTT + 5x10 mL CaCl₂|
|MRX171/172/173||Eximius Control Basic L1/L2/L3||10x1 mL pack per level|
|MRX181/182/183||Eximius Control PLUS L1/L2/L3||10x1 mL pack per level|
MRX APTT product line
MRX930APTT, lupus insensitive
APTT 5x5 mL
CaCl₂ 5x5 mL
MRX931APTT, lupus insensitive
APTT 5x10 mL
CaCl₂ 5X10 mL
MRX171Eximius Control Basic L1
MRX172Eximius Control Basic L2
MRX173Eximius Control Basic L3
MRX181Eximius Control PLUS L1
MRX182Eximius Control PLUS L2
MRX183Eximius Control PLUS L3
GHI155CaCl2, 100 mL
GHI155-5CaCl2, 5 mL
GHI155-2CaCl2, 2 mL
All Coagulation Reagents
MRX Fib Clauss
Lyophilised reagents for quantifying fibrinogen in human citrated plasma, according to the Clauss method.
FXa-based chromogenic assay consisting of liquid components for quantifying functional Antithrombin activity in human citrated plasma.
MRX PT Quick
PT reagent from rabbit brain origin with an ISI ~1 for responsive determination of Prothrombin Time in citrated human plasma.
Latex-based liquid component kits for quantifying D-dimer fragments in human citrated plasma using readers with wavelengths 350-900nm.
MRX Owren’s PT
The predominantly used PT method in Scandinavia due to the high sensitivity to interferences. The assay can be used with both whole blood and plasma.
MRX Thrombin Time
Lyophilised reagent with dual formats for detection of fibrinogen abnormalities, and the presence of heparin and other thrombin inhibitors in human citrated plasma.